GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis (RELINE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Flanders Medical Research Program
ClinicalTrials.gov Identifier:
NCT01108861
First received: April 21, 2010
Last updated: September 1, 2014
Last verified: September 2014
  Purpose

This is a prospective, randomized, multi-center study recruiting patients with an in-stent restenosis in the superficial femoral artery. The safety and efficacity of the Viabahn endoprosthesis (W.L. Gore & Associates), a heparin-bonded endoprosthesis, is compared with plain old balloon angioplasty (POBA). In 4 Belgian and 2 German centers a total of 80 Patients will be recruited. Primary endpoint is primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and without target lesion revascularization (TLR) within 12 months.

In comparison to POBA, it is expected that the use of the Viabahn endoprosthesis (W.L. Gore & Associates) will result in greater 12 month primary patency of treated superficial femoral artery in-stent restenotic lesions.


Condition Intervention Phase
Peripheral Vascular Disease
Device: GORE VIABAHN® Endoprosthesis
Device: Plain old balloon angioplasty
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis

Resource links provided by NLM:


Further study details as provided by Flanders Medical Research Program:

Primary Outcome Measures:
  • Primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) and without target lesion revascularization (TLR) within 12 months. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Proportion of subjects who experience serious device-related adverse events within 30 days post-procedure [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30%. [ Time Frame: during procedure ] [ Designated as safety issue: Yes ]
  • Hemodynamic primary patency rate at 1, 6, 12, 24-month follow-up. [ Time Frame: 1, 6, 12, 24-month follow-up ] [ Designated as safety issue: No ]
    Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (systolic velocity ratio no greater than 2.5) and without prior TLR are defined as being primary patent at the given follow-up.

  • Angiographic primary patency at 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Angiographic primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on no Quantitative Angiographic evidence of stenosis > 50%

  • Primary assisted patency rate at 1, 6, 12, 24-month follow-up. [ Time Frame: 1, 6, 12, 24-month follow-up ] [ Designated as safety issue: No ]
    Primary assisted patency rate at 1, 6, 12, 24-month follow-up. Defined as flow through the treated lesion maintained by repeat percutaneous intervention completed prior to complete vessel closure.

  • Secondary patency rate at 1, 6, 12, 24-month follow-up [ Time Frame: 1, 6, 12, 24-month follow-up ] [ Designated as safety issue: No ]
    Secondary patency rate at 1, 6, 12, 24-month follow-up. Defined as flow through the treated lesion maintained by repeat percutaneous intervention after occlusion of the target lesion.

  • Target lesion revascularization (TLR) [ Time Frame: entire follow-up ] [ Designated as safety issue: No ]
    Target lesion revascularization (TLR) is defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5 mm proximal and distal to the device/PTA edge

  • Clinical success at follow-up [ Time Frame: at 1 day and 1, 6, 12, 24-month follow-up ] [ Designated as safety issue: No ]
    Clinical success at follow-up is defined as an improvement of Rutherford classification at 1 day and 1, 6, 12, 24-month follow-up of one class or more as compared to the pre-procedure Rutherford classification.

  • Serious adverse events [ Time Frame: during entire follow-up ] [ Designated as safety issue: No ]
    Serious adverse events as defined as any clinical event that is fatal, life-threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or unduly prolonged hospitalization, necessitates an intervention to prevent a permanent impairment of a body function or permanent damage to a body structure, is a congenital abnormality/birth defect, a fetal distress or fetal death, results in malignancy

  • Stent fracture rate at 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]

    Stent fracture rate at 12 months, determined by using the following classifications on X-ray:

    1. Class 0 : no strut factures
    2. Class I : single tine fracture
    3. Class II : multiple tine factures
    4. Class III : Stent fracture(s) with preserved alignment of the components
    5. Class IV : Stent fracture(s) with mal-alignment of the components
    6. Class V : Stent fracture(s) in a trans-axial spiral configuration


Enrollment: 100
Study Start Date: May 2010
Study Completion Date: March 2014
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Endoprosthesis
GORE VIABAHN® Endoprosthesis
Device: GORE VIABAHN® Endoprosthesis
GORE VIABAHN® Endoprosthesis
Other Name: GORE VIABAHN® Endoprosthesis
Active Comparator: Plain old balloon angioplasty
Plain old balloon angioplasty
Device: Plain old balloon angioplasty
Plain old balloon angioplasty
Other Name: Plain old balloon angioplasty

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria:

  • Patient presenting with lifestyle-limiting claudication, rest pain or minor tissue loss (Rutherford classification from 2 to 5)
  • Patient is willing to comply with specified follow-up evaluations at the specified times
  • Patient is >18 years old
  • Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
  • Patient has a projected life-expectancy of at least 24 months
  • Noninvasive lower extremity arterial studies (resting or exercise) demonstrate ankle-brachial index ≤0.8
  • Patient is eligible for treatment with the Viabahn® Endoprosthesis (W.L. Gore)
  • Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure

Angiographic Inclusion Criteria

  • Restenotic or reoccluded lesion located in a stent which was previously implanted (>30 days) in the superficial femoral artery, suitable for endovascular therapy
  • Total target lesion length between 4 and 27 cm (comprising in-stent restenosis and adjacent stenotic disease)
  • Minimum of 1.0cm of healthy vessel (non-stenotic) both proximal and distal to the treatment area
  • Popliteal artery is patent at the intercondylar fossa of the femur to P3
  • Target vessel diameter visually estimated to be >4mm and <7.6 mm at the proximal and distal treatment segments within the SFA
  • Guidewire and delivery system successfully traversed lesion
  • There is angiographic evidence of at least one-vessel-runoff to the foot, that does not require intervention (<50% stenotic)

Exclusion criteria :

  • Untreated flow-limiting aortoiliac stenotic disease
  • Presence of a chronic total occlusion, i.e. a complete occlusion of the failed bare stent that cannot be re-opened with thrombolysis or does not allow easy passage of the guidewire by the physician
  • Any previous surgery in the target vessel
  • Severe ipsilateral common/deep femoral disease requiring surgical reintervention
  • Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
  • Femoral or popliteal aneurysm located at the target vessel
  • Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
  • No patent tibial arteries (>50% stenosis)
  • Prior ipsilateral femoral artery bypass
  • Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy
  • Serum creatinine >2.5mg/dL within 45 days prior to study procedure unless the subject is currently on dialysis
  • Major distal amputation (above the transmetatarsal) in the study or non-study limb
  • Septicemia or bacteremia
  • Any previously known coagulation disorder, including hypercoagulability
  • Contraindication to anticoagulation or antiplatelet therapy
  • Known allergies to stent or stent graft components (nickel-titanium or ePTFE)
  • Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
  • Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
  • Currently participating in another clinical research trial, unless approved by W.L. Gore & Associates in advance of study enrolment
  • Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment
  • Any planned surgical intervention/procedure within 30 days of the study procedure
  • Target lesion access not performed by transfemoral approach.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01108861

Locations
Belgium
Imelda Hospital
Bonheiden, Belgium, 2820
AZ Sint-Blasius
Dendermonde, Belgium, 9200
Universitair ziekenhuis antwerpen
Edegem, Belgium, 2650
Zuid Oost Limburg
Genk, Belgium, 3600
Germany
Herz-zentrum Bad Krozingen
Bad Krozingen, Germany, 79189
Herzzentrum
Leipzig, Germany, 04289
Sponsors and Collaborators
Flanders Medical Research Program
Investigators
Principal Investigator: Marc Bosiers, MD AZ Sint Blasius
  More Information

Additional Information:
No publications provided

Responsible Party: Flanders Medical Research Program
ClinicalTrials.gov Identifier: NCT01108861     History of Changes
Other Study ID Numbers: FMRP-100107
Study First Received: April 21, 2010
Last Updated: September 1, 2014
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
Belgium: Institutional Review Board
Germany: Ethics Commission

Keywords provided by Flanders Medical Research Program:
Peripheral Vascular Disease
In-stent restenosis
Endoprosthesis
Plain old balloon angioplasty

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Arteriosclerosis
Atherosclerosis
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 29, 2014